NCT05896228 2026-03-11
Iber-KDd
University of Miami
Phase 2 Recruiting
Clinical Trials
16 trialsNCT06083922 2026-03-06
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05289687 2026-03-02
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT06974786 2026-01-23
FASTER
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT05898646 2026-01-13
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
Phase 2 Recruiting
NCT05231629 2026-01-09
MASTER-2
University of Alabama at Birmingham
Phase 2 Recruiting
NCT04991103 2025-12-31
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Phase 2 Recruiting
NCT05695508 2025-12-24
HD10/DSMMXX
University of Heidelberg Medical Center
Phase 2 Recruiting
NCT06827860 2025-12-18
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT07110844 2025-11-19
Teclistamab-Daratumumab in AL Amyloidosis
Columbia University
Phase 2 Recruiting
NCT04176718 2025-10-07
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
Phase 2 Recruiting
NCT05572229 2025-09-17
IFM2021-01
University Hospital, Lille
Phase 2 Recruiting
NCT06015724 2025-07-28
DARANIVOVAX
Georgetown University
Phase 2 Recruiting
NCT07021677 2025-06-15
DARA_T_ALL
Tata Memorial Centre
Phase 2 Recruiting
NCT06505369 2024-07-17
TALTEC
North Estonia Medical Centre
Phase 2 Recruiting
NCT06189833 2024-04-23
TAURUS
European Myeloma Network B.V.
Phase 2 Recruiting